Reporting from: – Gastrointestinal Cancers Symposium, January 27-29, 2005, Hollywood, Florida In this edition: Bruce Giantonio and Robert Mayer discuss the Eastern Cooperative Oncology Group stu

Reporting from:
– Gastrointestinal Cancers Symposium, January 27-29, 2005, Hollywood, Florida
In this edition:
Bruce Giantonio and Robert Mayer discuss the Eastern Cooperative Oncology Group study in which bevacizumab was added to an oxaliplatinbased regimen for the management of advanced colorectal cancer previously treated with chemotherapy.
Heinz-Josef Lenz reports on an investigation showing single-agent cetuximab to be effective in the treatment of advanced colorectal cancer that is refractory to all of the usual cytotoxic drugs.
Malcolm Moore’s trial involving patients with advanced pancreatic cancer, in which gemcitabine standard therapy has been supplemented with erlotinib (a drug targeting the epidermal growth factor pathway), has shown a small but definite improvement in survival and disease control. Robert Mayer discusses the results.
Daniel Haller explains how his ONCOSURGE decision-making system for the treatment of colorectal cancer metastases can be applied to potentially extend life and even cure patients by helping clinicians decide which strategies to use in each particular clinical situation.
Tags
Related Episodes

Audio Journal of Oncology in Advance – March 1st, 2008
Volume 16 Number 5 (March 1st, 2008) reporting from: 4th European Congress on Hematologic Malignancies (February 22-24, 2008, Paris) Gastrointestinal Cancers Symposium (January 25-27, 2008, Orlando) A

Gastrointestinal Cancers: Progress with Targeted Therapies
Robert Mayer ROBERT MAYER, Dana-Farber Cancer Institute, Boston One of the leading participants at the 2008 Gastrointestinal Cancers Symposium, Robert Mayer, gave Peter Goodwin his assessment of some
